Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03978637 |
Recruitment Status :
Active, not recruiting
First Posted : June 7, 2019
Last Update Posted : March 10, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bronchiolitis Obliterans Syndrome | Drug: Itacitinib | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 23 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | Phase 1 Itacitinib administered orally followed by phase 2; Itacitinib administered orally at the recommended dose from Phase 1. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation |
Actual Study Start Date : | February 4, 2020 |
Estimated Primary Completion Date : | September 19, 2022 |
Estimated Study Completion Date : | September 19, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Itacitinib 300 mg
Phase 1: Itacitinib 300 mg twice daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
|
Drug: Itacitinib
Itacitinib administered orally at the specified dose.
Other Name: INCB039110 |
Experimental: Itacitinib 400 mg
Phase 1: Itacitinib 400 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
|
Drug: Itacitinib
Itacitinib administered orally at the specified dose.
Other Name: INCB039110 |
Experimental: Itacitinib 600 mg
Phase 1: Itacitinib 600 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration
|
Drug: Itacitinib
Itacitinib administered orally at the specified dose.
Other Name: INCB039110 |
Experimental: Itacitinib
Phase 2: Itacitinib administered orally at the recommended dose from Phase 1.
|
Drug: Itacitinib
Itacitinib administered orally at the specified dose.
Other Name: INCB039110 |
- Phase 1: Number of treatment-emergent adverse events [ Time Frame: Week 12 ]Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug until 30 days after the last dose of study drug.
- Phase 1: Change from baseline in forced expiratory volume in 1 second (FEV1) [ Time Frame: Week 12 ]
- Phase 2: Change from baseline in FEV1 response rate [ Time Frame: Week 12 ]Defined as the proportion of participants demonstrating a ≥ 10% absolute increase in FEV1 compared to baseline.
- Phase 1 and 2: Duration of FEV1 response [ Time Frame: Up to approximately 24 months ]Defined as the time of the onset of response (≥ 10% absolute increase in FEV1 compared to baseline) to BOS progression or loss of clinical benefit as determined by the investigator.
- Phase 1 and 2: Time to progression [ Time Frame: Up to approximately 24 months ]Defined as the interval between the start of treatment and BOS progression (≥ 10% absolute decrease in FEV1 compared to baseline), or death.
- Phase 1 and 2: Change from baseline in SGRQ total score [ Time Frame: Up to approximately 24 months ]St. Georges Respiratory Questionnaire, a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airway disease.
- Phase 1 and 2: Change from baseline in QOL-SF-12 questionnaire [ Time Frame: Up to approximately 24 months ]A 12-item subset of the SF-36 v2 scale that will capture changes in health status during the course of treatment.
- Phase 1 and 2: Categorical summary or change from baseline in EQ-5D-3L questionnaire [ Time Frame: Up to approximately 24 months ]A descriptive classification consisting of 5 dimensions of health: mobility, self-care, usual activities, anxiety/depression, and pain/discomfort.
- Phase 2: Overall Survival [ Time Frame: Up to approximately 24 months ]Defined as the interval between the start of treatment and the date of re-transplantation or death due to any cause.
- Phase 1 and 2: Cmax of itacitinib [ Time Frame: Up to Week 4 ]Maximum observed concentration.
- Phase 1 and 2: Cmin of itacitinib [ Time Frame: Up to Week 4 ]Minimum observed plasma or serum concentration over the dose interval.
- Phase 1 and 2: Tmax of itacitinib [ Time Frame: Up to Week 4 ]Time to maximum concentration.
- Phase 1 and 2: AUC0-t of itacitinib [ Time Frame: Up to Week 4 ]Area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t.
- Phase 1 and 2: Cl/F of itacitinib [ Time Frame: Up to Week 4 ]Apparent oral dose clearance.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Double lung transplantation ≥ 1 year before informed consent. Confirmed BOS progression to Grade 1, 2, or 3 diagnosed within 1 year of screening
*Confirmed BOS progression to Grade 1, 2, or 3 diagnosed within 2 years of screening AND:
- A ≥ 200 mL decrease in FEV1 in the previous 12 months
OR
*A ≥ 50 mL decrease in FEV1 in the last 2 measurements.
• Willingness to avoid pregnancy or fathering children.
Exclusion Criteria:
- History of a single lung transplant
- FEV1 decline attributable to cause(s) other than BOS.
- Participants who have had any significant change (eg, addition of new agents) in an immunosuppressive regimen in the 4 weeks before screening.
- Untreated and/or symptomatic gastroesophageal reflux disease.
- Significant infectious comorbidities including invasive fungal disease, B. Cepacia, non TB mycobacteria, or TB.
- Receipt of JAK inhibitor therapy after lung transplant for any indication. Treatment with a JAK inhibitor before lung transplant is permitted.
- Laboratory values at screening outside the protocol-defined ranges.
- Active HBV or HCV infection that requires treatment, or at risk for HBV reactivation (ie, positive HBsAg).
- Known HIV infection.
- History of active malignancy within 3 years of screening.
- Women who are pregnant or breastfeeding.
- Treatment with an investigational agent, procedure, or device within 30 days of enrollment, or within 5 half-lives of the investigational product, whichever is longer.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03978637
United States, California | |
University of California, Los Angeles - David Geffen School of Medicine | |
Los Angeles, California, United States, 90095 | |
United States, Massachusetts | |
Brigham and Women'S Faulkner Hospitals Inc | |
Boston, Massachusetts, United States, 02115 | |
United States, North Carolina | |
Duke University Health System | |
Durham, North Carolina, United States, 27710 | |
United States, Ohio | |
Cleveland Clinic | |
Cleveland, Ohio, United States, 44195 | |
United States, Pennsylvania | |
Hospital of the University of Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19104 | |
Temple University Department of Thoracic Medicine and Surgery | |
Philadelphia, Pennsylvania, United States, 19140 | |
UPMC | |
Pittsburgh, Pennsylvania, United States, 15213 | |
Belgium | |
Universitaire Ziekenhuis Leuven - Gasthuisberg | |
Leuven, Belgium, 03000 | |
Canada, Ontario | |
University Health Network Toronto General Hospital | |
Toronto, Ontario, Canada, M5G 2N2 |
Study Director: | Kevin O'Hayer, MD | Incyte Corporation |
Responsible Party: | Incyte Corporation |
ClinicalTrials.gov Identifier: | NCT03978637 |
Other Study ID Numbers: |
INCB 39110-214 |
First Posted: | June 7, 2019 Key Record Dates |
Last Update Posted: | March 10, 2022 |
Last Verified: | March 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Bronchiolitis obliterans syndrome lung transplant JAK1 inhibitor |
Bronchiolitis Bronchiolitis Obliterans Syndrome Disease Pathologic Processes Bronchitis |
Respiratory Tract Infections Infections Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |